Patients with HER2 gene amplification, normal left ventricular ejection fraction (LVEF), and resistant relapse after first- or second-line paclitaxel/carboplatin chemotherapy received paclitaxel ...

Herceptin has since revolutionized treatment outcomes and recurrence rates associated with the disease, which are now comparable with that of HER2-normal breast cancer, and in some cases, even better, ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.